Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epeleuton in COPD
NCT03414541Phase 2Completed
- Sponsor
- Afimmune
- Start
- Sep 2017
- Primary completion
- Jan 2019
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of epeleuton in chronic obstructive pulmonary disease (COPD), sponsored by Afimmune. Started Sep 2017; status: completed.
02
Drugs
epeleuton
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03414541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03414541.